Home › Chronic Lymphocytic Leukemia › California › Los Angeles
Chronic Lymphocytic Leukemia clinical trials in Los Angeles, CA
8 studies for Chronic Lymphocytic Leukemia are looking for participants at sites in and around Los Angeles (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
RecruitingPhase 3
- Kaiser Permanente Los Angeles Medical Center, Los Angeles
- Kaiser Permanente West Los Angeles, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
RecruitingPhase 3
- Kaiser Permanente Los Angeles Medical Center, Los Angeles
- Kaiser Permanente West Los Angeles, Los Angeles
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
RecruitingPhase 3
- UCLA Department of Medicine Hematologyoncology, Los Angeles
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RecruitingPhase 3
- UCLA Department of Medicine Hematologyoncology, Los Angeles
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
RecruitingPhase 2
- Cedars-Sinai Medical Center, Los Angeles
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RecruitingPhase 1/2
- Valkyrie Clinical Trials, Los Angeles
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
RecruitingPhase 1/2
- Los Angeles Cancer Network, Los Angeles
- UCLA Medical Center of Hematology/Oncology, Los Angeles
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
RecruitingPhase 3
- Valkyrie Clinical Trials /ID# 268151, Los Angeles
Chronic Lymphocytic Leukemia trials in other cities
- Boston, MA31 studies
- Columbus, OH28 studies
- Durham, NC27 studies
- Washington, DC22 studies
- Seattle, WA20 studies
- Rochester, MN18 studies
- New York City, NY18 studies
- Houston, TX17 studies
- Baldwin Park, CA16 studies
- Milwaukee, WI15 studies
- Chicago, IL14 studies
- Cincinnati, OH14 studies
Other studies in Los Angeles
- Non-Small Cell Lung Cancer87 studies
- Cancer (all types)74 studies
- Breast Cancer73 studies
- Prostate Cancer61 studies
- Colorectal Cancer59 studies
- Metastatic Cancer57 studies
- Ovarian Cancer50 studies
- Lung Cancer45 studies
- Head and Neck Squamous Cell Carcinoma42 studies
- Pancreatic Cancer35 studies
- Endometrial Cancer34 studies
- Melanoma34 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.